Current news stories
Personalised treatments for cancer sufferers have moved a step closer with the
appointment of Dr Jeanette Kunz as a Senior Research Fellow in Molecular Cancer
Therapeutics at The University of Auckland.
A New Zealand-designed compound that shows promise against treatment-resistance
tuberculosis (TB) has been selected as a drug candidate by international
non-profit drug developer the Global Alliance for TB Drug Development (TB
The US Food and Drug Administration (FDA) has granted approval for PR610, an
anticancer “stealth” drug invented in New Zealand, to move forward to human
clinical trials through its approval of an Investigational New Drug (IND)
Application for the drug.
“Standard cancer therapies attack healthy tissue as well as cancer cells,
causing side effects that can limit treatment,” explains Associate Professor
Michael Hay from the ACSRC at The University of Auckland and the Maurice Wilkins
Centre. “By designing new drugs that target some of the abnormal biological
processes unique to cancer cells, it may be possible to fight cancer with
minimal side effects.”
A second anticancer “stealth” drug designed by New Zealand scientists has been
targeted for clinical development under a collaborative agreement between
Proacta Incorporated (San Diego) and Yakult Honsha Co., Ltd. (Tokyo).
Events and seminars
The ACSRC Seminar Series 2012 runs weekly on Fridays between 1-2pm*
For further information please contact Jack Flanagan.
* Times may vary